We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Idexx Laboratories (IDXX) Stock Moves -0.76%: What You Should Know
Read MoreHide Full Article
Idexx Laboratories (IDXX - Free Report) closed at $487.66 in the latest trading session, marking a -0.76% move from the prior day. This change traded in line with S&P 500. At the same time, the Dow lost 0.94%, and the tech-heavy Nasdaq lost 1.12%.
Coming into today, shares of the Animal diagnostic and health care company had lost 8.48% in the past month. In that same time, the Medical sector lost 0.52%, while the S&P 500 gained 1.74%.
Investors will be hoping for strength from IDXX as it approaches its next earnings release. The company is expected to report EPS of $1.74, up 34.88% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $739.2 million, up 18.02% from the prior-year quarter.
IDXX's full-year Zacks Consensus Estimates are calling for earnings of $7.59 per share and revenue of $3.09 billion. These results would represent year-over-year changes of +13.11% and +14.3%, respectively.
Investors should also note any recent changes to analyst estimates for IDXX. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. IDXX is currently a Zacks Rank #2 (Buy).
Valuation is also important, so investors should note that IDXX has a Forward P/E ratio of 64.72 right now. Its industry sports an average Forward P/E of 38.52, so we one might conclude that IDXX is trading at a premium comparatively.
Also, we should mention that IDXX has a PEG ratio of 4.09. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. IDXX's industry had an average PEG ratio of 3.08 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 164, which puts it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Idexx Laboratories (IDXX) Stock Moves -0.76%: What You Should Know
Idexx Laboratories (IDXX - Free Report) closed at $487.66 in the latest trading session, marking a -0.76% move from the prior day. This change traded in line with S&P 500. At the same time, the Dow lost 0.94%, and the tech-heavy Nasdaq lost 1.12%.
Coming into today, shares of the Animal diagnostic and health care company had lost 8.48% in the past month. In that same time, the Medical sector lost 0.52%, while the S&P 500 gained 1.74%.
Investors will be hoping for strength from IDXX as it approaches its next earnings release. The company is expected to report EPS of $1.74, up 34.88% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $739.2 million, up 18.02% from the prior-year quarter.
IDXX's full-year Zacks Consensus Estimates are calling for earnings of $7.59 per share and revenue of $3.09 billion. These results would represent year-over-year changes of +13.11% and +14.3%, respectively.
Investors should also note any recent changes to analyst estimates for IDXX. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. IDXX is currently a Zacks Rank #2 (Buy).
Valuation is also important, so investors should note that IDXX has a Forward P/E ratio of 64.72 right now. Its industry sports an average Forward P/E of 38.52, so we one might conclude that IDXX is trading at a premium comparatively.
Also, we should mention that IDXX has a PEG ratio of 4.09. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. IDXX's industry had an average PEG ratio of 3.08 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 164, which puts it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.